Detalhe da pesquisa
1.
Reassessing potential economic value and health impact of effective Shigella vaccines.
Bull World Health Organ
; 102(1): 65-74, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38164339
2.
Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis.
J Infect Dis
; 219(9): 1464-1473, 2019 04 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30423128
3.
Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays.
Antimicrob Agents Chemother
; 62(6)2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29555627
4.
Ensuring access to affordable, timely vaccines in emergencies.
Bull World Health Organ
; 97(12): 851-853, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31819295
5.
Shigella and childhood stunting: Evidence, gaps, and future research directions.
PLoS Negl Trop Dis
; 17(9): e0011475, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37699032
6.
Potential impact and cost-effectiveness of Shigella vaccination in 102 low-income and middle-income countries in children aged 5 years or younger: a modelling study.
Lancet Glob Health
; 11(6): e880-e891, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37202023
7.
Projecting the long-term economic benefits of reducing Shigella-attributable linear growth faltering with a potential vaccine: a modelling study.
Lancet Glob Health
; 11(6): e892-e902, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37202024
8.
Vaccine value profile for Shigella.
Vaccine
; 41 Suppl 2: S76-S94, 2023 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37827969
9.
What Drives the Value of a Shigella Vaccine?
Vaccines (Basel)
; 10(2)2022 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35214740
10.
Could a Shigella vaccine impact long-term health outcomes?: Summary report of an expert meeting to inform a Shigella vaccine public health value proposition, March 24 and 29, 2021.
Vaccine X
; 12: 100218, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36237199
11.
New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya.
Bull World Health Organ
; 87(3): 186-92, 192A-192B, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19377714
12.
Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.
Int J Parasitol
; 46(13-14): 871-880, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27729271
13.
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.
J Med Chem
; 59(13): 6531-46, 2016 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-27309760
14.
SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1.
ACS Med Chem Lett
; 6(12): 1184-1189, 2015 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26693272
15.
Reassessing potential economic value and health impact of effective Shigella vaccines
Bull. W.H.O. (Print)
; 102(1): 65-74, 2024.
Artigo
em Inglês
| WHOLIS | ID: who-375551
16.
Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold.
ACS Med Chem Lett
; 5(1): 40-44, 2014 Jan 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-24494061
17.
Health statistics: time to get serious.
Bull World Health Organ
; 83(10): 722, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16283042
18.
New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya
Bull. W.H.O. (Print)
; 87(3): 186-192, 2009-3.
Artigo
em Inglês
| WHOLIS | ID: who-270396
19.
Health statistics: time to get serious.
Bull. W.H.O. (Print)
; 83(10): 722-722, 2005-10.
Artigo
em Inglês
| WHOLIS | ID: who-269498